Update on gastroesophageal reflux disease.
Ledger
Séadna
S
London Health Sciences Centre, Ontario. Seadna.Ledger@lhsc.on.ca
D000863:Antacids / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005764:Gastroesophageal Reflux / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D008019:Life Style; D008134:Long-Term Care; D018579:Patient Selection; D054328:Proton Pump Inhibitors; D012720:Severity of Illness Index
D000863:Antacids; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors